VIVUS Earnings Preview: 3 Things to Watch

What should investors watch for in Q4?

Max Macaluso
Max Macaluso
Feb 20, 2013 at 5:22PM
Health Care

Instead of celebrating VIVUS' (NASDAQ:VVUS) drug launch last quarter, shareholders were shocked to hear the company report thin sales and see the stock's share price cut by a whopping 20%. The company is set to report its fourth-quarter results -- the first full quarter featuring Qsymia sales -- on Feb. 25, and investors are wondering whether this biotech can regain its momentum. Should they continue tracking sales, or are there other issues that deserve equal attention? Health-care analyst Max Macaluso dives into this topic in the following video.